EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Analytical Validation of a Second-Generation Methotrexate Immunoassay

Rebecca Wilson, Diane Yamaguchi, Jamie Garrett, Michael Schmeling, Erin Kuest, Andrew N Hoofnagle iD

The Journal of Applied Laboratory Medicine · 2026

DOI: 10.1093/jalm/jfaf166 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Rebecca Wilson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, OH, United States. Hauptthemen laut MEDLINE: Methotrexate, Drug Monitoring, Folic Acid Antagonists. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ark Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methotrexate, an antifolate therapy, is used for the treatment of cancers, autoimmune disease, and transplant patients and needs to be carefully monitored for toxicity. Plasma measurement of methotrexate concentrations is problematic as a result of analytical interference of its metabolites. Immunoassays are widely used for monitoring therapeutic drug levels of methotrexate; however, chromatographic assays, LC-MS/MS most particularly, are preferentially used since they are less prone to metabolite interference.

Methods

Analytical performance was evaluated in a second-generation methotrexate immunoassay (ARK, Inc.) by testing precision, accuracy, linearity, interference, and method comparison with LC-MS/MS. Cross-reactivity of the immunoassay with 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA), 7-OH methotrexate, and folic acid was also measured.

Results

Findings indicate that the within-run %CV ranged from 2.6% to 4.4% across control materials. The assay was linear across an analytical measuring range of 0.03 to 1.3 μM. The lower limit of the measuring interval and the lower limit of detection were established at 0.03 µM and 0.0067 μM, respectively. Notable interference from DAMPA was observed above 1 µM, whereas 7-OH methotrexate and folic acid showed no interference up to 5 µM and 1000 µM, respectively. Correlation studies showed an average 3% bias in DAMPA-free samples (R2 = 0.9935) and a significant bias and poorer correlation (R2 = 0.3241) in samples containing DAMPA.

Conclusions

The assay performed well based on the validation experiments and is suitable for most clinical applications involving methotrexate. However, the significant interference with DAMPA highlights the necessity for careful assay selection and interpretation of glucarpidase-treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateDrug MonitoringFolic Acid AntagonistsHumansImmunoassayReproducibility of ResultsTandem Mass SpectrometryFolic AcidChromatography, LiquidLimit of DetectionCross Reactions

Substanzen

MethotrexateFolic AcidFolic Acid Antagonists

Autor:innen und Institutionen

  • Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital, Cincinnati, OH, United States.
  • Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, United States.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, United States.
  • Departmant of Medicine, University of Washington, Seattle, WA, United States.

ORCID-Profile: Andrew N Hoofnagle

Förderung

  • Ark Diagnostics

Zitieren

APA

Wilson, R., Yamaguchi, D., Garrett, J., Schmeling, M., Kuest, E., & Hoofnagle, A. N. (2026). Analytical Validation of a Second-Generation Methotrexate Immunoassay. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf166

Vancouver

Wilson R, Yamaguchi D, Garrett J, Schmeling M, Kuest E, Hoofnagle AN. Analytical Validation of a Second-Generation Methotrexate Immunoassay. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfaf166

BibTeX
@article{Wilson2026,
  author = {Wilson, Rebecca and Yamaguchi, Diane and Garrett, Jamie and Schmeling, Michael and Kuest, Erin and Hoofnagle, Andrew N},
  title = {Analytical Validation of a Second-Generation Methotrexate Immunoassay},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2026},
  doi = {10.1093/jalm/jfaf166}
}
Kostenlos starten →